Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3, randomized, double-blind, parallel-group, multinational trial of intravenous telavancin versus vancomycin for treatment of hospital-acquired pneumonia with a focus on patients with infections due to methicillin-resistant Staphylococcus aureus

X
Trial Profile

A phase 3, randomized, double-blind, parallel-group, multinational trial of intravenous telavancin versus vancomycin for treatment of hospital-acquired pneumonia with a focus on patients with infections due to methicillin-resistant Staphylococcus aureus

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telavancin (Primary) ; Vancomycin
  • Indications Methicillin-resistant Staphylococcus aureus infections; Nosocomial pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms ATTAIN 1
  • Sponsors Innoviva; Theravance; Theravance Biopharma
  • Most Recent Events

    • 15 Oct 2019 Results published in the Infectious Diseases and Therapy.
    • 12 Jul 2018 Results of a retrospective renal shift analysis comparing the timing and extent of renal function changes during treatment with either telavancin or vancomycin using the safety population (n=1503) from the ATTAIN trials (NCT00107952 and NCT00124020), published in the Pharmacotherapy Journal.
    • 01 Sep 2017 Results of post hoc analysis of data from the ATLAS and ATTAIN trials assessing efficacy and safety of Telavancin in patients with Concurrent Staphylococcus aureus Bacteremia, were published in the Infectious Diseases and Therapy.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top